• Protease Inhibitors
• NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)
• NRTIs (Nucleoside Reverse Transcriptase Inhibitors)
• Entry Inhibitors
• Other Side Effect Warnings
• Antibiotics

This chart may not adequately reflect the percentages of side effects in women due to the limited number of women in many studies of these drugs.

The colors underneath each drug heading below indicate the rough percentage of people reporting each side effect for each drug. See key at the bottom of each section.

	Reported in > 15% of people in clinical studies		Reported in 5–15% of people in clinical studies		Reported in < 5% of people in clinical studies
(blank)	Side effect has not been reported	C	Reported only in children, or more commonly in children	‡	Potentially fatal side effect

Protease Inhibitors (PI)
Drug Effects on Lab Values
	APV	ATV	fos APV	IDV		LPV	NFV	RTV	SQV (hgc)	SQV (sgc)
Anemia (low red blood/hemoglobin count)
Leukopenia (low white blood cell count)
Neutropenia (low neutrophil count)
Thrombo- cytopenia (low platelet count)						C
Elevated Alkaline Phosphatase (liver)
Elevated Amylase (pancreas)
Elevated Bilirubin (liver)						C
Elevated Cholesterol
Elevated Creatinine (kidney)
Elevated Glucose (blood sugar)
Elevated Liver Functions
Elevated Triglycerides (cholesterol)
Drug Side Effects
	APV	ATV	fos APV	IDV		LPV	NFV	RTV	SQV (hgc)	SQV (sgc)
Abdominal pain
Altered taste
Anorexia (reduced appetite)
Arthralgia (joint pain)
Chills
Constipation
Depression
Diarrhea
Dizziness
Fatigue
Fevers
Headache
Insomnia (sleep problems)
Malaise
Menstrual Irregularities
Myalgia (muscle pain)
Nausea
Nephrolithiasis (kidney stones)
Neurological Symptoms
Neuropathy (pain/tingling in arms arms/legs/hands/feet)					C
Pancreatitis (inflammation of the pancreas)	‡	‡	‡	‡		‡	‡	‡	‡	‡
Paresthesia (numbness, prickling, tingling)
Rash	‡	‡	‡	‡			‡		‡
Seizures
Vomiting

APV = Amprenavir;     ATV = Atazanavir;      fosAPV = Fosamprenavir;     IDV = Indinavir;
LPV = Lopinavir + RTV;     NFV = Nelfinavir;     RTV = Ritonavir;
SQV(hgc) = Saquinavir hard gel capsule;   SQV(sgc) = Saquinavir soft gel capsule

	Reported in > 15% of people in clinical studies		Reported in 5–15% of people in clinical studies		Reported in < 5% of people in clinical studies
(blank)	Side effect has not been reported	C	Reported only in children, or more commonly in children	‡	Potentially fatal side effect

DLV = Delavirdine;     EFV = Efavirenz;     NVP = Nevirapine

	Reported in > 15% of people in clinical studies		Reported in 5–15% of people in clinical studies		Reported in < 5% of people in clinical studies
(blank)	Side effect has not been reported	C	Reported only in children, or more commonly in children	‡	Potentially fatal side effect

ABV=Abacavir;     Combivir = AZT + 3TC;     Trizivir = AZT + 3TC + ABV
FTC=Emtricitabine;     TNV = Tenofovir

	Reported in > 15% of people in clinical studies		Reported in 5–15% of people in clinical studies		Reported in < 5% of people in clinical studies
(blank)	Side effect has not been reported	C	Reported only in children, or more commonly in children	‡	Potentially fatal side effect

T20 = Enfuvirtide

	Reported in > 15% of people in clinical studies		Reported in 5–15% of people in clinical studies		Reported in < 5% of people in clinical studies
(blank)	Side effect has not been reported	C	Reported only in children, or more commonly in children	‡	Potentially fatal side effect

Other Side Effect Warnings All Anti-HIV Drugs Changes in body fat distribution, called lipodystrophy, have been associated both with HIV infection and anti-HIV therapy. A warning about lipodystrophy is now included in the label information for all anti-HIV drugs. All Nucleoside Analogs A build-up of lactic acid in the body (lactic acidosis) and severe liver enlargement (hepatomegaly) with fatty liver (steatosis), including fatal cases, have been reported with using NRTIs alone or in combination. Fatal lactic acidosis has been reported in pregnant women who took d4T (stavudine, Zerit) and ddI (didanosine, Videx) with other anti-HIV drugs. The combination of d4T and ddI should be used with caution during pregnancy. AZT AZT (zidovudine, Retrovir) has been associated with low neutrophil counts (neutropenia) and severe reductions in red blood cells (anemia), particularly in patients with advanced HIV disease. Prolonged use of AZT has been associated with muscle weakness (myopathy). Abacavir Fatal hypersensitivity reactions have occurred in up to 8.5% of people taking abacavir (Ziagen). People with fever, skin rash, fatigue, nausea, vomiting, diarrhea, abdominal pain, and/or respiratory symptoms are advised to call their doctor immediately and stop using abacavir if directed, as soon as a hypersensitivity reaction is suspected. Once abacavir treatment is stopped, it should be permanently discontinued as a more severe reaction may recur within hours if it is restarted and may include life-threatening symptoms and death. d4T/ddI Fatal and non-fatal inflammation in the pancreas (pancreatitis) has occurred with the combination of d4T and ddI. Neither d4T nor ddI should be used in people with suspected or confirmed pancreatitis. Enfuvirtide Nearly 100% of people using enfuvirtide (T20, Fuzeon) will have injection site reactions including redness, inflammation, pain and hardening of the skin.